MECOM and nasopharyngeal carcinoma: Recently, arsenite loaded nanoparticles were shown to exhibit anti-tumor activity against EVI1-positive nasopharyngeal carcinoma cell lines both in vitro and in a xenograft model [9], raising the possibility that arsenic compounds may also be effective in solid tumors with high EVI1 expression, including in HNSCC.